相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy
John A. Hartley
EXPERT OPINION ON BIOLOGICAL THERAPY (2021)
Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin
Abdullah Ladha et al.
LEUKEMIA & LYMPHOMA (2021)
HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells
Vianihuini Figueroa-Vazquez et al.
MOLECULAR CANCER THERAPEUTICS (2021)
A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma
Christian Kollmannsberger et al.
ONCOLOGIST (2021)
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study
Fiona Blackhall et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: An open-label, dose-escalation, phase I study
Ruoxi Hong et al.
CANCER COMMUNICATIONS (2021)
Dolaflexin: A Novel Antibody-Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect
Aleksandr Yurkovetskiy et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Site-selective modification strategies in antibody-drug conjugates
Stephen J. Walsh et al.
CHEMICAL SOCIETY REVIEWS (2021)
Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Xinan Sheng et al.
CLINICAL CANCER RESEARCH (2021)
Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy
Sajad Yaghoubi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
Efficacy of the Antibody-Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors
Barbara Akla et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Antibody prodrugs for cancer
W. Michael Kavanaugh
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Targeting anti-apoptotic BCL-2 family proteins for cancer treatment
Xuan Zhang et al.
FUTURE MEDICINAL CHEMISTRY (2020)
Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models
Eugenio Gaudio et al.
HAEMATOLOGICA (2020)
TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors
Marco Gymnopoulos et al.
MOLECULAR ONCOLOGY (2020)
Characterization of IgG1 Fc Deamidation at Asparagine 325 and Its Impact on Antibody-dependent Cell-mediated Cytotoxicity and FcγRIIIa Binding
Xiaojun Lu et al.
SCIENTIFIC REPORTS (2020)
SKB264 ADC: A first-in-human study of SKB264 in patients with locally advanced unresectable/metastatic solid tumors who are refractory to available standard therapies.
Yongheng Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
SGN228-001: A phase I open-label dose-escalation, and expansion study of SGN-CD228A in select advanced solid tumors.
Amita Patnaik et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Dose escalation and expansion from the phase I study of DS-1062, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients (pts) with advanced non-small cell lung cancer (NSCLC).
Aaron Elliott Lisberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
First-in-human dose-escalation study of anti-EGFR ADC MRG003 in patients with relapsed/refractory solid tumors.
Rui-hua Xu et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
First-in-human phase I study of anti-HER2 ADC MRG002 in patients with relapsed/refractory solid tumors.
Jin Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Reducing the antigen-independent toxicity of antibody-drug conjugates by minimizing their non-specific clearance through PEGylation
Jessica K. Simmons et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2020)
Recent advances of antibody drug conjugates for clinical applications
Pengxuan Zhao et al.
ACTA PHARMACEUTICA SINICA B (2020)
The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1
Mercedes Nadal-Serrano et al.
CANCERS (2020)
Novel HER2-targeted therapies for HER2-positive metastatic breast cancer
Siddharth Kunte et al.
CANCER (2020)
Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1
Alison Betts et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2020)
ARX788, a Site-specific Anti-HER2 Antibody-Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1-resistant Breast and Gastric Cancers
Lillian Skidmore et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors
Stephanie Decary et al.
CLINICAL CANCER RESEARCH (2020)
Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer
Juniper A. Scribner et al.
MOLECULAR CANCER THERAPEUTICS (2020)
SGN-B6A: A new MMAE ADC targeting integrin beta-6 in multiple carcinoma indications
Robert P. Lyon et al.
CANCER RESEARCH (2020)
Co-administered antibody improves penetration of antibody-dye conjugate into human cancers with implications for antibody-drug conjugates
Guolan Lu et al.
NATURE COMMUNICATIONS (2020)
The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by 89Zr-immuno-PET in xenograft bearing mice
Marion Chomet et al.
THERANOSTICS (2020)
Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
Giorgio Frega et al.
ONCOIMMUNOLOGY (2020)
Liver Complications Following Treatment of Hematologic Malignancy With Anti-CD22-Calicheamicin (Inotuzumab Ozogamicin)
George B. McDonald et al.
HEPATOLOGY (2019)
Improved Inhibition of Tumor Growth by Diabody-Drug Conjugates via Half-Life Extension
Qing Li et al.
BIOCONJUGATE CHEMISTRY (2019)
Cutting-edge multi-level analytical and structural characterization of antibody-drug conjugates: present and future
Alain Beck et al.
EXPERT REVIEW OF PROTEOMICS (2019)
HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
Gabriel Rinnerthaler et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial
Johann S. de Bono et al.
LANCET ONCOLOGY (2019)
Characterization of Disulfide Bond Rebridged Fab-Drug Conjugates Prepared Using a Dual Maleimide Pyrrolobenzodiazepine Cytotoxic Payload
Ben T. Ruddle et al.
CHEMMEDCHEM (2019)
Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b.
Anthony W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors.
George D. Demetri et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The Analysis of Key Factors Related to ADCs Structural Design
Haichao Tang et al.
FRONTIERS IN PHARMACOLOGY (2019)
Conjugation of DM1 to anti-CD30 antibody has potential antitumor activity in CD30-positive hematological malignancies with lower systemic toxicity
Yijun Shen et al.
MABS (2019)
Site-specific antibody-drug conjugate heterogeneity characterization and heterogeneity root cause analysis
Mingyan Cao et al.
MABS (2019)
The Utility of Highly Toxic Marine-Sourced Compounds
David J. Newman
MARINE DRUGS (2019)
Lysosomal P-gp-MDR1 Confers Drug Resistance of Brentuximab Vedotin and Its Cytotoxic Payload Monomethyl Auristatin E in Tumor Cells
Peggy Liu-Kreyche et al.
FRONTIERS IN PHARMACOLOGY (2019)
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study
Daniel Morgensztern et al.
CLINICAL CANCER RESEARCH (2019)
Effect of Size on Solid Tumor Disposition of Protein Therapeutics
Zhe Li et al.
DRUG METABOLISM AND DISPOSITION (2019)
Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study
Thomas Boyer et al.
CANCERS (2019)
Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS)
Tiziana Vaisitti et al.
BLOOD (2019)
An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates
Haleh Saber et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2019)
CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia
Evgeniya Angelova et al.
HAEMATOLOGICA (2019)
Secreted Gal-3BP is a novel promising target for non-internalizing Antibody-Drug Conjugates
Francesco Giansanti et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells
Krista Kinneer et al.
LEUKEMIA (2019)
APOMAB Antibody-Drug Conjugates Targeting Dead Tumor Cells are Effective In Vivo
Alexander H. Staudacher et al.
MOLECULAR CANCER THERAPEUTICS (2019)
An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC
Kimio Yonesaka et al.
ONCOGENE (2019)
Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer
Louise A. Koopman et al.
JCI INSIGHT (2019)
NBE-002, an anthracycline-based immune-stimulatory antibody drug conjugate (iADC) targeting ROR1 for the treatment of triple-negative breast cancer
Roger R. Beerli et al.
CANCER RESEARCH (2019)
CAT-02-106, a Site-Specifically Conjugated Anti-CD22 Antibody Bearing an MDR1-Resistant Maytansine Payload Yields Excellent Efficacy and Safety in Preclinical Models
Penelope M. Drake et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Site-specific and hydrophilic ADCs through disulfide-bridged linker and branched PEG
Shuai Shao et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies
Francesca Zammarchi et al.
BLOOD (2018)
LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates
James W. Purcell et al.
CANCER RESEARCH (2018)
Resistance to Antibody-Drug Conjugates
Sara Garcia-Alonso et al.
CANCER RESEARCH (2018)
Extending the limits of size exclusion chromatography: Simultaneous separation of free payloads and related species from antibody drug conjugates and their aggregates
Alexandre Goyon et al.
JOURNAL OF CHROMATOGRAPHY A (2018)
Practical approaches for overcoming challenges in heightened characterization of antibody-drug conjugates with new methodologies and ultrahigh-resolution mass spectrometry
Olga V. Friese et al.
MABS (2018)
Challenges and new frontiers in analytical characterization of antibody-drug conjugates
Anil Wagh et al.
MABS (2018)
FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
Kelly J. Norsworthy et al.
ONCOLOGIST (2018)
Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia
Jeffrey Baron et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2018)
Discovery and activity of STRO-002, a novel ADC targeting folate receptor alpha for ovarian and endometrial cancer
Xiaofan Li et al.
CANCER RESEARCH (2018)
A phase 1/2 dose-escalation and expansion study of a conditionally active anti-AXL humanized monoclonal antibody (BA3011) in patients with advanced solid tumors.
Jordi Rodon Ahnert et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity
Xin Cheng et al.
MOLECULAR CANCER THERAPEUTICS (2018)
T-DM1-resistant cells gain high invasive activity via EGFR and integrin cooperated pathways
Yukinori Endo et al.
MABS (2018)
Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001
Cristina L. Abrahams et al.
Oncotarget (2018)
A Polar Sulfamide Spacer Significantly Enhances the Manufacturability, Stability, and Therapeutic Index of Antibody-Drug Conjugates
Jorge M. M. Verkade et al.
ANTIBODIES (2018)
Hydrophilic Auristatin Glycoside Payload Enables Improved Antibody-Drug Conjugate Efficacy and Biocompatibility
Tero Satomaa et al.
ANTIBODIES (2018)
From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs)
Julia Mantaj et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2017)
ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence
Jieyi Wang et al.
CLINICAL CANCER RESEARCH (2017)
Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix
Remy Gebleux et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance
Naoki Takegawa et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Charge variants characterization of a monoclonal antibody by ion exchange chromatography coupled on-line to native mass spectrometry: Case study after a long-term storage at+5 °C
Y. Leblanc et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2017)
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study
Kathleen N. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A non-internalizing antibody-drug conjugate based on an anthracycline payload displays potent therapeutic activity in vivo
Alberto Dal Corso et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
Charles M. Rudin et al.
LANCET ONCOLOGY (2017)
Insights from native mass spectrometry approaches for top- and middle- level characterization of site-specific antibody-drug conjugates
Thomas Botzanowski et al.
MABS (2017)
Strategies and challenges for the next generation of antibody drug conjugates
Alain Beck et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study
Hagop M. Kantarjian et al.
LANCET HAEMATOLOGY (2017)
The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models
Stuart W. Hicks et al.
NEOPLASIA (2017)
The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates
Mark Frigerio et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2017)
Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease
Mark A. Socinski et al.
CLINICAL LUNG CANCER (2017)
Imaged capillary isoelectric focusing in native condition: A novel and successful example
Xin Zhang et al.
ANALYTICAL BIOCHEMISTRY (2017)
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study
Martin van den Bent et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates
Xiuxia Sun et al.
BIOCONJUGATE CHEMISTRY (2017)
Investigation of Hydrophilic Auristatin Derivatives for Use in Antibody Drug Conjugates
Brian A. Mendelsohn et al.
BIOCONJUGATE CHEMISTRY (2017)
Structural Characterization of a Monoclonal Antibody-Maytansinoid Immunoconjugate
Quanzhou Luo et al.
ANALYTICAL CHEMISTRY (2016)
A sensitive multidimensional method for the detection, characterization, and quantification of trace free drug species in antibody-drug conjugate samples using mass spectral detection
Robert E. Birdsall et al.
MABS (2016)
Structural characterization of antibody drug conjugate by a combination of intact, middle-up and bottom-up techniques using sheathless capillary electrophoresis - Tandem mass spectrometry as nanoESI infusion platform and separation method
Nassur Said et al.
ANALYTICA CHIMICA ACTA (2016)
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naive, HER2-positive, locally advanced/metastatic breast cancer
Kathy Miller et al.
BMC CANCER (2016)
ABiparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
John Y. Li et al.
CANCER CELL (2016)
Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer
Christopher W. Espelin et al.
CANCER RESEARCH (2016)
Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
Pia M. Challita-Eid et al.
CANCER RESEARCH (2016)
Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
Yusuke Ogitani et al.
CANCER SCIENCE (2016)
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Yusuke Ogitani et al.
CLINICAL CANCER RESEARCH (2016)
Linkers Having a Crucial Role in Antibody-Drug Conjugates
Jun Lu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells
Daniel W. Sherbenou et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Practical method development for the separation of monoclonal antibodies and antibody-drug-conjugate species in hydrophobic interaction chromatoraphy, part 2: Optimization of the phase system
Alessandra Cusumano et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2016)
Physical and Chemical Stability of Antibody Drug Conjugates: Current Status
Philip L. Ross et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2016)
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
Heather Donaghy
MABS (2016)
Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design
Magdalena Dorywalska et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins
Prince Awuah et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Mechanisms of Resistance to Antibody-Drug Conjugates
Frank Loganzo et al.
MOLECULAR CANCER THERAPEUTICS (2016)
ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Michael J. Flynn et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Straightforward Glycoengineering Approach to Site-Specific Antibody-Pyrrolobenzodiazepine Conjugates
Pamela Thompson et al.
ACS MEDICINAL CHEMISTRY LETTERS (2016)
Posttranslational Modifications and the Immunogenicity of Biotherapeutics
Roy Jefferis
JOURNAL OF IMMUNOLOGY RESEARCH (2016)
hLL2-Cys-PBD, a New Site-Specifically Conjugated, Pyrrolobenzodiazepine (PBD) Dimer-Based Antibody Drug Conjugate (ADC) Targeting CD22-Expressing B-Cell Malignancies.
Francesca Zammarchi et al.
BLOOD (2016)
Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry
Jessica R. McCombs et al.
AAPS JOURNAL (2015)
Current methods for the synthesis of homogeneous antibody-drug conjugates
Alicja M. Sochaj et al.
BIOTECHNOLOGY ADVANCES (2015)
A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity
Xuejing Yao et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Antibody-targeted drugs and drug resistance-Challenges and solutions
LeeRon Shefet-Carasso et al.
DRUG RESISTANCE UPDATES (2015)
A size exclusion-reversed phase two dimensional-liquid chromatography methodology for stability and small molecule related species in antibody drug conjugates
Yi Li et al.
JOURNAL OF CHROMATOGRAPHY A (2015)
Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials
Joshua Seth Eaton et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2015)
Characterization of Cysteine-Linked Conjugation Profiles of Immunoglobulin G1 and Immunoglobulin G2 Antibody-Drug Conjugates
Brian Wiggins et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2015)
Tumor Cells Chronically Treated with a Trastuzumab-Maytansinoid Antibody-Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
Frank Loganzo et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates
Remy Gebleux et al.
MOLECULAR CANCER THERAPEUTICS (2015)
CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin
Robert Chen et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases
Vashti Irani et al.
MOLECULAR IMMUNOLOGY (2015)
In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab-MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody Ratios
Penny Bryant et al.
MOLECULAR PHARMACEUTICS (2015)
Evolving Strategies for Target Selection for Antibody-Drug Conjugates
Marc Damelin et al.
PHARMACEUTICAL RESEARCH (2015)
Current ADC Linker Chemistry
Nareshkumar Jain et al.
PHARMACEUTICAL RESEARCH (2015)
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
Laura R. Saunders et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
David M. Goldenberg et al.
ONCOTARGET (2015)
T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2
Roberta Nicoletti et al.
CLINICAL & EXPERIMENTAL METASTASIS (2015)
Innovative Native MS Methodologies for Antibody Drug Conjugate Characterization: High Resolution Native MS and IM-MS for Average DAR and DAR Distribution Assessment
Francois Debaene et al.
ANALYTICAL CHEMISTRY (2014)
Bridging Disulfides for Stable and Defined Antibody Drug Conjugates
George Badescu et al.
BIOCONJUGATE CHEMISTRY (2014)
Auristatin Antibody Drug Conjugate Physical Instability and the Role of Drug Payload
Yilma T. Adem et al.
BIOCONJUGATE CHEMISTRY (2014)
Production of Site-Specific Antibody-Drug Conjugates Using Optimized Non-Natural Amino Acids in a Cell-Free Expression System
Erik S. Zimmerman et al.
BIOCONJUGATE CHEMISTRY (2014)
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
Yu-Tzu Tai et al.
BLOOD (2014)
Trastuzumab emtansine: mechanisms of action and drug resistance
Mark Barok et al.
BREAST CANCER RESEARCH (2014)
Curative Properties of Noninternalizing Antibody-Drug Conjugates Based on Maytansinoids
Elena Perrino et al.
CANCER RESEARCH (2014)
Antibody-drug conjugates: current status and future directions
Heidi L. Perez et al.
DRUG DISCOVERY TODAY (2014)
SGN-LIV1A: A Novel Antibody-Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer
Django Sussman et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody-Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
Sven Golfier et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar
Zhongyu Zhu et al.
MABS (2014)
Antibody-Drug Conjugates in Cancer Therapy
Eric L. Sievers et al.
ANNUAL REVIEW OF MEDICINE, VOL 64 (2013)
Total Antibody Quantification for MMAE-Conjugated Antibody-Drug Conjugates: Impact of Assay Format and Reagents
Katherine R. Kozak et al.
BIOCONJUGATE CHEMISTRY (2013)
Investigation into Temperature-Induced Aggregation of an Antibody Drug Conjugate
Nia S. Beckley et al.
BIOCONJUGATE CHEMISTRY (2013)
The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer
Christopher H. Keir et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates
Mauro Acchione et al.
MABS (2012)
Site-specific chemical protein conjugation using genetically encoded aldehyde tags
David Rabuka et al.
NATURE PROTOCOLS (2012)
Synthesis of site-specific antibody-drug conjugates using unnatural amino acids
Jun Y. Axup et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Antibody Conjugate Therapeutics: Challenges and Potential
Beverly A. Teicher et al.
CLINICAL CANCER RESEARCH (2011)
Analytical methods for physicochemical characterization of antibody drug conjugates
Aditya Wakankar et al.
MABS (2011)
Advances in the assessment and control of the effector functions of therapeutic antibodies
Xu-Rong Jiang et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Physicochemical Stability of the Antibody-Drug Conjugate Trastuzumab-DM1: Changes due to Modification and Conjugation Processes
Aditya A. Wakankar et al.
BIOCONJUGATE CHEMISTRY (2010)
Post-translational Modifications Differentially Affect IgG1 Conformation and Receptor Binding
Damian Houde et al.
MOLECULAR & CELLULAR PROTEOMICS (2010)
Cell adhesion molecules nectins and associating proteins: Implications for physiology and pathology
Hisakazu Ogita et al.
PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2010)
Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma
David Dornan et al.
BLOOD (2009)
CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma
Akihiro Takeshita et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
Gail D. Lewis Phillips et al.
CANCER RESEARCH (2008)
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Jagath R. Junutula et al.
NATURE BIOTECHNOLOGY (2008)
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies
JF DiJoseph et al.
BLOOD (2004)
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate
KJ Hamblett et al.
CLINICAL CANCER RESEARCH (2004)
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity
JA Francisco et al.
BLOOD (2003)
Hepatic veno-occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin (CMA-676) immunoconjugate
P Neumeister et al.
ANNALS OF HEMATOLOGY (2001)
分享论文
